BACKGROUND: Soluble ST2 (sST2) is an emerging prognostic biomarker in patients with existing cardiovascular disease. ST2 and its ligand, interleukin-33 (IL-33), are expressed in endothelial cells, and may play an important role in the development of early atherosclerosis and vascular biology. We sought to investigate the association of sST2 and progression of blood pressure (BP), as well as the development of hypertension. METHODS: Circulating sST2 concentrations were measured in 1834 participants (mean age 56 years, 57% women) of the community-based Framingham Offspring study. Participants were free of hypertension at baseline. Multivariable linear and logistic regression models were used to evaluate the association of sST2 concentrations and subsequent BP outcomes. RESULTS: Higher sST2 concentrations were associated with incident hypertension over 3 years of follow-up [multivariable-adjusted odds ratio per 1 standard deviation increase in sST2 1.22, 95% confidence interval 1.05-1.42, P=0.01]. Individuals in the upper sST2 quartile had a 2.6 mmHg greater increase in SBP compared with those in the lowest quartile (P for trend across quartiles 0.002) and a 1.8 mmHg greater increase in pulse pressure (P for trend 0.005). In contrast, sST2 concentrations were not associated with changes in DBP (P=0.27). CONCLUSION: These findings suggest that sST2 concentrations predict changes in BP physiology typically seen with aging and progressive arterial stiffness. Further studies are needed to elucidate underlying mechanisms by which the ST2/IL-33 pathway may contribute to BP physiology.
BACKGROUND: Soluble ST2 (sST2) is an emerging prognostic biomarker in patients with existing cardiovascular disease. ST2 and its ligand, interleukin-33 (IL-33), are expressed in endothelial cells, and may play an important role in the development of early atherosclerosis and vascular biology. We sought to investigate the association of sST2 and progression of blood pressure (BP), as well as the development of hypertension. METHODS: Circulating sST2 concentrations were measured in 1834 participants (mean age 56 years, 57% women) of the community-based Framingham Offspring study. Participants were free of hypertension at baseline. Multivariable linear and logistic regression models were used to evaluate the association of sST2 concentrations and subsequent BP outcomes. RESULTS: Higher sST2 concentrations were associated with incident hypertension over 3 years of follow-up [multivariable-adjusted odds ratio per 1 standard deviation increase in sST2 1.22, 95% confidence interval 1.05-1.42, P=0.01]. Individuals in the upper sST2 quartile had a 2.6 mmHg greater increase in SBP compared with those in the lowest quartile (P for trend across quartiles 0.002) and a 1.8 mmHg greater increase in pulse pressure (P for trend 0.005). In contrast, sST2 concentrations were not associated with changes in DBP (P=0.27). CONCLUSION: These findings suggest that sST2 concentrations predict changes in BP physiology typically seen with aging and progressive arterial stiffness. Further studies are needed to elucidate underlying mechanisms by which the ST2/IL-33 pathway may contribute to BP physiology.
Authors: Ravi V Shah; Annabel A Chen-Tournoux; Michael H Picard; Roland R J van Kimmenade; James L Januzzi Journal: Circ Heart Fail Date: 2009-05-14 Impact factor: 8.790
Authors: Saskia Boisot; Jennifer Beede; Susan Isakson; Albert Chiu; Paul Clopton; James Januzzi; Alan S Maisel; Robert L Fitzgerald Journal: J Card Fail Date: 2008-07-26 Impact factor: 5.712
Authors: Jeffrey A Cutler; Paul D Sorlie; Michael Wolz; Thomas Thom; Larry E Fields; Edward J Roccella Journal: Hypertension Date: 2008-10-13 Impact factor: 10.190
Authors: Benjamin Dieplinger; James L Januzzi; Martin Steinmair; Christian Gabriel; Werner Poelz; Meinhard Haltmayer; Thomas Mueller Journal: Clin Chim Acta Date: 2009-08-20 Impact factor: 3.786
Authors: Jozef Bartunek; Leen Delrue; Frederik Van Durme; Olivier Muller; Filip Casselman; Bart De Wiest; Romaric Croes; Sofie Verstreken; Marc Goethals; Herbert de Raedt; Jaydeep Sarma; Lija Joseph; Marc Vanderheyden; Ellen O Weinberg Journal: J Am Coll Cardiol Date: 2008-12-16 Impact factor: 24.094
Authors: Marc S Sabatine; David A Morrow; Luke J Higgins; Catherine MacGillivray; Wei Guo; Christophe Bode; Nader Rifai; Christopher P Cannon; Robert E Gerszten; Richard T Lee Journal: Circulation Date: 2008-03-31 Impact factor: 29.690
Authors: Kenjiro Seki; Shoji Sanada; Anastacia Y Kudinova; Matthew L Steinhauser; Vandna Handa; Joseph Gannon; Richard T Lee Journal: Circ Heart Fail Date: 2009-09-22 Impact factor: 8.790
Authors: Meagan E Stabler; Michael E Rezaee; Devin M Parker; Todd A MacKenzie; Andrew R Bohm; Anthony W DiScipio; David J Malenka; Jeremiah R Brown Journal: Biomarkers Date: 2019-01-11 Impact factor: 2.658
Authors: Charlotte Andersson; Danielle Enserro; Lisa Sullivan; Thomas J Wang; James L Januzzi; Emelia J Benjamin; Joseph A Vita; Naomi M Hamburg; Martin G Larson; Gary F Mitchell; Ramachandran S Vasan Journal: Atherosclerosis Date: 2016-02-18 Impact factor: 5.162
Authors: Charlotte Andersson; Sarah R Preis; Alexa Beiser; Charles DeCarli; Kai C Wollert; Thomas J Wang; James L Januzzi; Ramachandran S Vasan; Sudha Seshadri Journal: Stroke Date: 2015-07-28 Impact factor: 7.914